Cannabinoid compositions with high solubility and bioavailability

Abstract

The present invention is based on the highly soluble and bioavailable cannabinoid compositions which can be made at a commercial scale with a simple manufacturing process. Thus, the present invention relates to oral compositions comprising a cannabinoid compound, for use in the nutraceutical, pharmaceutical, food or beverage industries and its production methods.

1 . An oral composition comprising at least one cannabinoid compound, at least one emulsifier, at least one silica derivative and at least one cyclodextrin compound, wherein a weight ratio of the cyclodextrin compound to the emulsifier is between 1:0.5 to 1:25. 
     
     
         2 . The oral composition of  claim 1 , wherein the cannabinoid compound is selected from a group consisting of cannabidiols, cannabichromenes, cannabinols, cannabigerols or derivatives and combinations thereof. 
     
     
         3 . The oral composition of  claim 1 , wherein the cannabinoid compound is selected from a group consisting of Δ9-tetrahydrocannabinol (THC), Δ8-tetrahydrocannabinol, Δ9-tetrahydrocannabinol propyl analogue (THCV), cannabidiol (CBD), cannabidiol propyl analogue (CBDV), cannabinol (CBN), cannabichromene, cannabichromene propyl analogue and cannabigerol or derivatives and combinations thereof. 
     
     
         4 . The oral composition of  claim 3 , wherein the cannabinoid compound is selected from the group consisting of Δ9-tetrahydrocannabinol (THC), Δ9-tetrahydrocannabinol propyl analogue (THCV), cannabidiol (CBD) and combinations thereof. 
     
     
         5 . (canceled) 
     
     
         6 . The oral composition of  claim 1 , wherein the weight ratio of the cyclodextrin compound to the emulsifier is between 1:1 to 1:15. 
     
     
         7 . The oral composition according to of  claim 1 , wherein the weight ratio of cannabinoid compound to the cyclodextrin compound is between 1:0.1 to 2:1. 
     
     
         8 . The oral composition of  claim 7 , wherein the weight ratio of the cannabinoid compound to the cyclodextrin compound is between 1:0.1 to 1:1. 
     
     
         9 . The oral composition of  claim 1 , wherein the weight ratio of the cannabinoid compound to the silica derivative is between 1:0.1 to 0.1:1. 
     
     
         10 . The oral composition of  claim 1 , wherein the emulsifier has an HLB value between 10 and 25. 
     
     
         11 . The oral composition of  claim 1 , wherein the emulsifier is selected from a group consisting of polyoxethylene derivatives, sorbitan esters, polyethylene glycol derivatives and a combination thereof. 
     
     
         12 . The oral composition of  claim 1 , wherein the emulsifier is selected from a group consisting of tearoyl polyoxyl-32 glycerides, lauroyl polyoxyl-32 glycerides or polyoxy-ethylene sucrose diester dimyristate, Polyoxy-ethylene sucrose diester dinnyristate, polyoxy-ethylene sucrose diester dipalmitate, polyoxy-ethylene sucrose diester dioleate, polysorbate 80, polysorbate 60, polysorbate 20, PEG-8 laurate, PEG 400 monoluarate, PEG 10 isooctylphenyl ether, PEG 40 stearate, PEG 50 stearate, PEG 40 isooctylphenyl ether, sodium stearoyl-2-lactylate, sodium stearoyl lactylate and a combination thereof. 
     
     
         13 . The oral composition of  claim 1 , wherein the emulsifier is a polyoxylglyceride or a polysorbate (sorbitan ester). 
     
     
         14 . The oral composition of  claim 13 , wherein the emulsifier is selected from a group consisting of stearoyl polyoxyl-32 glycerides, lauroyl polyoxyl-32 glycerides, polysorbate 80, polysorbate 60, polysorbate 20, and a combination thereof. 
     
     
         15 . The oral composition of  claim 1 , wherein the cyclodextrin compound is selected from a group consisting of α-cyclodextrin, γ-cyclodextrin, β-cyclodextrin, 2-hydroxypropyl-β-cyclodextrin, sulfobutylether β-cyclodextrin sodium salt, randomly methylated β-cyclodextrin, branched β-cyclodextrin, γ-cyclodextrin and derivatives thereof. 
     
     
         16 . The oral composition of  claim 15 , wherein the cyclodextrin compound is selected from the group consisting of β-cyclodextrin, 2-hydroxypropyl-β-cyclodextrin, sulfobutylether β-cyclodextrin sodium salt, randomly methylated β-cyclodextrin, and branched β-cyclodextrin. 
     
     
         17 . The oral composition of  claim 16 , wherein the cyclodextrin compound is β-cyclodextrin. 
     
     
         18 . The oral composition of  claim 1 , wherein the silica derivative is hydrophilic. 
     
     
         19 . The oral composition of  claim 1 , wherein the silica derivatives have a mean particle diameter of between 10 to 250 microns. 
     
     
         20 . The oral composition of  claim 1 , wherein the silica derivatives have a BET surface area between 40 to 400 m 2 /g. 
     
     
         21 . The oral composition of  claim 1 , wherein the silica derivatives have a tamped density between 50 to 600 g/L. 
     
     
         22 . The oral composition according to  claim 21 , wherein the silica derivatives have a tamped density between 50 to 400 g/L. 
     
     
         23 . The oral composition of  claim 1 , wherein the silica derivative is selected from colloidal silicon dioxide, calcium silicate, or magnesium aluminometasilicate. 
     
     
         24 . The oral composition of  claim 1 , wherein a pH of the composition is in the range of 3 to 7.2. 
     
     
         25 . The oral composition of  claim 24 , wherein a pH of the composition is in the range of 5 to 7.2. 
     
     
         26 . A method for producing an oral composition comprising:
 mixing a cannabinoid compound with an emulsifier or cyclodextrin compound; and   mixing the cannabinoid compound with a silica derivative.   
     
     
         27 . The method of  claim 26 , further comprising the steps of:
 mixing the cannabinoid compound and the emulsifier under room temperature with a high shear mixer;   adding the cyclodextrin compound;   adding the silica derivative until the oral composition turns into a powder; and   sieving the powder through a 200 μm to 2000 μm sieve.